$1.52
+0.05 (+3.40%)
Open$1.50
Previous Close$1.47
Day High$1.54
Day Low$1.35
52W High$4.19
52W Low$1.09
Volume—
Avg Volume115.0K
Market Cap115.79M
P/E Ratio—
EPS$-1.65
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,900.0% upside
Current
$1.52
$1.52
Target
$30.40
$30.40
$22.94
$30.40 avg
$39.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.14M | 24.88M | 53.29M |
| Net Income | -214,396,541 | -1,320,959,060 | -9,463,863 |
| Profit Margin | -3,492.3% | -5,603.4% | -17.8% |
| EBITDA | -154,540,893 | -1,395,170,020 | -11,859,784 |
| Free Cash Flow | — | — | -9,841,834 |
| Rev Growth | +183.3% | -45.3% | -6.8% |
| Debt/Equity | 10.79 | 2.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |